Tuesday, May 12, 2009

Cryo-Cell releases new study in stem cell research

Cryo-Cell International, Inc. announced breakthrough results of a new study during the Annual Meeting of the International Society Of Cellular Therapy (ISCT) which was held at San Diego, California early May, 2009. According to the CryoCell Press Release , it is found that adding menstrual blood stem cells, also known as MenSCs, to stem cells from umbilical cord blood expands the number of progenitor cells. Progenitor cells are cells that grow into mature blood cells. This expansion technique could broaden the therapeutic use of the cells and provide more readily available supply of stem cells for transplantation.

Cord blood stem cells are readily and easy to collect. Stem cells found in cord blood have been proven to treat more than 70 life-threatening diseases including leukemia, neuroblastoma, lymphoma and sickle cell anemia. However, umbilical cord blood can only be collected at birth and does not yield a sufficient number of stem cells typically needed for transplantation ( only enough stem cells for a child or smaller adult). With this limitations, studies are being done to identify ways to enhance or expand cord blood stem cells.

Studies were performed by using harvested cells from menstrual blood and cord blood cells collected after childbirth and processed to reduce the number of red blood cells. The culture results demonstrated an increase in the functional capacity of the cord blood stem cells with the addition of MenSCs or Menstrual Blood Stem Cells. MenSCs is a non-controversial and renewable stem cell source from what is conventionally regarded as biological waste. Cyro-Cell discovered the benefits of MenSCs and researchers believe that it may be utilized in the future to treat serious conditions such as diabetes, heart conditions, stroke and possibly other disorders such as Alzheimer's and Parkinson's disease.

Cyro-Cell introduced Celle in 2007, the first and only service that empowers women to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future usage by the donor or possibly first degree relatives in the same manner as umbilical cord blood stem cells. To read more about MenSCs and the ground breaking service, head over to their website at http://www.celle.com/


No comments: